Urologists, Radiologists, Patients Benefit From New Clinical Prostate Visualization System

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Radiology / Nuclear Medicine
Article Date: 01 Oct 2009 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The introduction of Invivo Corporation's DynaCAD for Prostate advanced clinical visualization and MR interventional system brings new hope to patients and new confidence to their care providers, a positive development this Prostate Cancer Awareness Month.

A five-year collaborative effort with Fox Chase Cancer Center, PA; Radboud University of Nijmegen, The Netherlands; University of Chicago, IL; and Desert Medical Imaging, CA resulted in an advanced solution that combines imaging and intervention options for patients with elevated or rising PSA levels and negative TRUS-guided biopsy results. DynaCAD for Prostate and DynaTRIM (Trans-Rectal Interventional MRI) allow Urologists, Oncologists and Radiologists to offer their patients an alternative to remaining in an uncertain state of diagnosis.

DynaCAD for Prostate provides physicians with customizable, advanced visualization tools for real-time analysis of MRI studies. Together with DynaTRIM, physicians can conduct targeted MRI interventions of suspicious areas within the prostate, reducing the number of cores acquired during biopsy. According to Dr. John Feller, Chief Medical Officer at Desert Medical Imaging, "DynaCAD for Prostate provides increased operational efficiency, enabling radiologists to rapidly interpret 3,000 images that constitute a dynamic contrast-enhanced prostate MRI."

Many patients who present with an elevated PSA undergo multiple TRUS-guided biopsies with negative results. While the TRUS targets the whole prostate, DynaTRIM focuses only on suspicious areas. "The results of our clinical evaluation revealed that DynaCAD for Prostate and DynaTRIM offer a better alternative for appropriate patients, and those results have been duplicated in the daily practices of physicians," said Susan Reisker, Product Marketing Manager at Invivo Corporation. "We're seeing patients traveling to centers where this advanced solution is now available and finally receiving firm diagnosis after experiencing multiple negative TRUS-guided biopsies." Dr. Inge von Oort, Oncological Urologist at the University of Nijmegen Medical Center, agrees. "Especially for patients who've had several negative biopsies, a maximum of only 4 MR-guided biopsy cores is required with a detection rate of 59%." Reisker adds, "Compared to published cancer yield rates of up to 15% with third TRUS-guided biopsies, the increased detection rate gives greater confidence to physicians and patients."

In addition to improved diagnostic abilities, physicians benefit from the scalability and cost-effective nature of DynaCAD for Prostate. Whether they require stand-alone workstations or broad enterprise systems, Invivo provides cost-effective upgrades to accommodate physicians' increased volume. "We developed this solution with patients' well-being and physicians' practices in mind," said Reisker. "DynaCAD for Prostate's flexible interface, alongside DynaTRIM, can easily become an important part of any practice interested in prostate imaging and intervention."

Invivo Corporation has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices. Invivo successfully develops, manufactures and markets high-value-added medical instruments that enhance MR image quality, improving physicians' diagnostic confidence and patients' health care experience.

Source: Invivo Corporation